|
IRZSMU >
Кафедри >
Кафедра внутрішніх хвороб 2 >
Наукові праці. (ВХ-2) >
Пожалуйста, используйте этот идентификатор, чтобы цитировать или ссылаться на этот ресурс:
http://dspace.zsmu.edu.ua/handle/123456789/3727
|
| Название: | The Rationality to Use of Galectin-3 as Target in Biomarker-Guided Therapy of Type 2 Diabetes Mellitus |
| Авторы: | Berezin, A. E.
Березін, Олександр Євгенійович |
| Ключевые слова: | Diabetes mellitus
Biomarkers
Galectin-3
Risk stratification
Targeting for therapy |
| Дата публикации: | 2016 |
| Библиографическое описание: | Berezin A. The Rationality to Use of Galectin-3 as Target in Biomarker-Guided Therapy of Type 2 Diabetes Mellitus [Electronic resource] / A. Berezin // Endocrinology & Metabolic Syndrome. – 2016. – Vol. 5, № 1. – p. 3. |
| Аннотация: | Galectin-3 is a multifunctional chimaera-type β-galactoside binding protein that has been linked to incident Cardiovascular (CV) and renal disease, fibrosis and tissue injury. Elevated level of serum galectin-3 was found in patients with Type 2 Diabetes Mellitus (T2DM) and associate well with CV complications. The short commentary depicts the role of galectin-3 in risk stratification in T2DM individuals. Although perspectives of clinical implementation of galectin-3-guided therapy in T2DM patients are widely discussed, there is evidence regarding cyto-protective role of galectin-3 in diabetes. Whether is rationale to achieve full control under serum galectin-3 as a predictor of successful T2DM treatment is not clear. Further investigations are needed to explain the role of galectin-3 in T2DM development and progression. |
| URI: | http://dspace.zsmu.edu.ua/handle/123456789/3727 |
| Располагается в коллекциях: | Наукові праці. (ВХ-2)
|
Все ресурсы в архиве электронных ресурсов защищены авторским правом, все права сохранены.
|
